MAPK8 and ovarian carcinoma: In addition, we pretreated with pharmacological inhibitors, including LY294002 (a PI3K inhibitor, 20 μM), U0126 (an ERK1/2 inhibitor, 20 μM), SP600125 (a JNK inhibitor, 20 μM), and SB203580 (a P38 inhibitor, 20 μM), before the treatment with fucosterol in order to identify the fucosterol-associated signal crosstalk in ovarian cancer cells (Figure 5).